Abstract
Bladder outlet obstruction (BOO)-related detrusor hypertrophy is associated with upregulation of Rho-kinase (ROCK) activity in an experimental animal model, and has been implicated in BOO-induced bladder dysfunction. The aim of this study was to test whether chronic oral administration of an oral ROCK inhibitor, fasudil (HA1077, 5-isoquinolinesulfonyl homopiperazine), could prevent the development of both detrusor hypertrophy and detrusor overactivity in rat model. Thirty five-week-old male Sprague-Dawley rats were divided into three groups (n = 10 per group): control (sham surgical) with no treatment (group 1); 6-week obstructed rats (group 2); and 6-week obstructed rats treated for 6 weeks with fasudil (group 3). The BOO group showed increased detrusor overactivity. Treatment with fasudil partly but significantly ameliorated the development of detrusor overactivity. The expression of RhoA protein in detrusor muscle was significantly greater in the BOO group than in the control group and subsequently decreased with fasudil treatment in the BOO-induced rat. These findings suggest that fasudil, a specific inhibitor of Rho-kinase, ameliorates BOO-induced detrusor overactivity in a rat model. Thus, ROCK inhibitor might be used as a novel agent to treat overactive bladder symptoms.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
